KKR backed in Qingdao Haier at a time when the Chinese white goods giant wanted to expand overseas and address competitive pressure at home. The GP helped it deliver on both fronts
Advantech Capital has led a $55 million Series B funding round for China’s Connect Biopharmaceuticals with support from Qiming Venture Partners.
US insurance giant Aflac has invested $20 million in Singapore Life, a digitally-focused financial technology start-up backed by UK private equity investor IPGL.
Lightspeed China Partners has closed its latest US dollar-denominated fund at $560 million. It is the largest fund raised by the firm to date and brings assets under management to $1.5 billion.
Antengene Corporation, a Chinese biopharmaceutical company focused on oncology drugs and therapies, has raised $120 million in a Series B round led by Boyu Capital and FountainVest Partners.
Futu Securities International, a Hong Kong-based online brokerage backed by Sequoia Capital China and Matrix Partners China, has filed to list in the US.
CLSA Capital Partners (CLSA CP) has acquired 100% of Ecolo Holdings, a Japanese parking lot business that operates primarily under the name Ecolocity.
By making the shopping experience more enjoyable and efficient, Chinese social e-commerce player has achieved scale at breakneck speed. A bumper US public offering was its reward
Tencent Holdings has led a $300 million round of funding for Chinese online education start-up Yuanfudao, propelling the company to a valuation in excess of $3 billion.
Japan’s Polaris Capital Group has agreed to buy Hitachi Automotive Systems Measurement (HASM), an automotive components subsidiary of Hitachi Corporation.
Australian mid-market buyout firm Next Capital has agreed to buy NZ Bus, a local bus service operator in New Zealand, from infrastructure investment manager Infratil.
KKR-backed Radiant Life Care is taking majority control of Indian hospital operator Max Healthcare, three months after agreeing to buy a 49.7% stake held by South Africa’s Life Healthcare Group.
The board of Australian accounting software provider MYOB has agreed to back a buyout offer from KKR that values the company at approximately A$2 billion ($1.43 billion).
Brookfield Asset Management expects to proceed with a A$4.49 billion ($3.16 billion) take-private offer for Australia-listed hospital operator Healthscope, although BGH Capital – which began its pursuit of the company eight months ago – has indicated...
Hong Kong-based Bowtie Life Insurance has raised $30 million in Series A funding and become the first company in the territory to receive a “virtual” license to provide online-only services.
Naspers has re-upped in Indian online food ordering and delivering platform Swiggy, leading a $1 billion Series H round of funding for the company.
A string of private equity investors backed Ant Financial’s $14 billion Series C round, having recognized a company at the forefront of financial disruption in China
CITIC Capital Partners and FountainVest Partners have acquired a majority stake in China Merchants Loscam, a pallet and packaging business owned by Sinotrans, for RMB2.48 billion ($359 million).
KKR has reduced its offer for Australian accounting software provider MYOB and is now willing to buy all the shares it doesn’t already own at a valuation of A$2 billion ($1.43 billion).
India-based ride-hailing platform Ola has committed $100 million worth of inventory to domestic scooter sharing business Vogo. It is part of a Series A round that also features Matrix Partners India and Stellaris Venture Partners.
Clifford Chance has launched a start-up incubator focused on legal technology and innovation in Singapore.
US-based private equity firm Strattam Capital has acquired a majority stake in Australian workforce management software-as-a-service provider Acendre Partners for an undisclosed sum.
AsiaInfo Technologies, a Chinese telecom software provider that was privatized by a CITIC Capital-led consortium in 2014, has raised HK$899.3 million ($115 million) in its Hong Kong IPO.
Motilal Oswal Private Equity (MOPE) and healthcare-focused GP Invascent Capital have invested in Indian pharmaceutical developer Symbiotec Pharmalab, providing an exit for Actis Capital.